Executive Profile*

Peter S. Greenleaf

AgeTotal Calculated CompensationThis person is connected to 124 board members in 4 different organizations across 9 different industries.

See Board Relationships
46$3,152,375

Background*

Mr. Peter S. Greenleaf has been the Chairman and Chief Executive Officer of Sucampo Pharmaceuticals, Inc. since January 1, 2016 and March 03, 2014 respectively. Mr. Greenleaf served as Chief Executive Officer of Histogenics Corporation from June 10, 2013 to February 28, 2014 and served as its President. He served as President of MedImmune, LLC (also known as MedImmune, Inc.). He also served as President of MedImmune Ventures, a wholly owned venture capital fund within ...

Read Full Background

Corporate Headquarters*

One MedImmune Way
Gaithersburg, Maryland 20878

United States

Phone: 301-398-3000
Fax: 301-398-8170

Board Members Memberships*

Director
2014-Present
Chairman and Chief Executive Officer
2015-Present
Director
2016-Present
Director

Education*

MBA
Saint Joseph's University
BS
Western Connecticut State University

Other Affiliations*

Annual Compensation*

Salary$565,288
Total Annual Compensation$565,288

Stock Options*

All Other Compensation$8,843
Exercisable Options350,000
Exercisable Options Value$3,428,000
Unexercisable Options860,000
Unexercisable Options Value$6,756,700
Total Value of Options$10,184,700
Total Number of Options1,210,000

Total Compensation*

Total Annual Cash Compensation$1,166,510
Total Short Term Compensation$565,288
Other Long Term Compensation$8,843
Total Calculated Compensation$3,152,375
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President and Director
Innoviva, Inc.
$721.4K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science Committee
Progenics Pharmaceuticals, Inc.
$597.1K
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals, Inc.
$691.5K
A. J. Kazimi MBAFounder, Chairman, Chief Executive Officer and President
Cumberland Pharmaceuticals Inc.
$720.0K
John Anthony Sedor Chairman and Chief Executive Officer
Pernix Therapeutics Holdings, Inc.
--
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.